Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
561.00    69.60 (14.16%)
Bid:
560.50
Ask:
561.00
Spread: 0.50 (0.089%)
Market Cap: £2.48b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

2 Apr 2015 07:00

2 April 2015 – Tate & Lyle PLC

STATEMENT ON ENTERING CLOSE PERIOD

Tate & Lyle PLC issues the following update for the year ended 31 March 2015 ahead of the announcement of full year results on 28 May 2015.

Based on trading performance for the fourth quarter there is no change from the guidance in our trading statement on 6 February 2015. We continue to expect Group adjusted profit before tax for the year ended 31 March 2015 to be modestly below the range stated in September 2014 of £230 to £245 million1.

As expected, for the full year, Group adjusted operating profit has been held back by the impact of the operational and supply chain issues experienced mainly in the first half, and the continued extremely competitive market for SPLENDA® Sucralose.

We expect net debt at 31 March 2015 to be around £500 million, higher than reported at 31 December 2014 (£466 million), principally due to investment in working capital as we continue to rebuild inventories and an exchange translation impact of around £20 million following further strengthening of the US dollar.

As planned, the project to evaluate how best to maximise returns from SPLENDA® Sucralose is reaching conclusion and will be finalised with the Board during April. We expect to communicate the outcome in the next few weeks.

On 24 February 2015 we launched DOLCIA PRIMATM Allulose, a low-calorie sugar, the most significant example of the innovation capability we established three years ago at our Commercial and Food Innovation Centre in Chicago. Since the launch, we have seen encouraging early interest and engagement from customers across a range of applications, and this supports our confidence in its longer term potential. However, given the relatively long development and adoption cycles for new ingredients, we do not expect it to have any material effect on the Group’s performance during the next financial year.

END

1 Range based on forecast foreign exchange rates of GBP:USD £1.00:$1.69 in September 2014.

Conference call:

A conference call will be held today at 8:00am BST, hosted by Javed Ahmed, Chief Executive and Nick Hampton, Chief Financial Officer. Participants are requested to dial in at least 10 minutes before the commencement of the call.

Dial in details are as follows:

Standard International Access: +44 (0) 20 3003 2666Password: Tate & LyleUK replay number: +44 (0) 20 3350 6902Replay access PIN: 1711809

A replay of this call will be available after the end of the live call for 14 days until 15 April 2015.

For more information contact Tate & Lyle PLC:

Christopher Marsh, Group VP, Investor and Media RelationsTel: +44 (0) 20 7257 2110 or Mobile: +44 (0) 7796 192 688

Andrew Lorenz, FTI Consulting (Media)Tel: +44 (0) 20 3727 1323 or Mobile: +44 (0) 7775 641 807

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, with operations in over 30 locations worldwide.

Tate & Lyle operates through two global divisions, Speciality Food Ingredients and Bulk Ingredients, supported by our Innovation and Commercial Development and Global Operations groups. The Group's strategy is to become a leading global provider of Speciality Food Ingredients through a disciplined focus on growth, and by driving Bulk Ingredients for sustained cash generation to fuel this growth.

Speciality Food Ingredients consists of three platforms: Texturants, which includes speciality starches and stabilisers; Sweeteners, which comprises nutritive sweeteners and our range of no-calorie sweeteners including SPLENDA® Sucralose; and our Health and Wellness portfolio which includes speciality fibres and our salt-reduction offering. Additionally, our Food Systems business provides a wide variety of blended ingredient solutions.

Tate & Lyle Bulk Ingredients includes bulk sweeteners, industrial starches and fermentation products (primarily acidulants). Corn co-products from both divisions are primarily sold as animal feed.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2014, Tate & Lyle sales totalled £3.1 billion. For more information, please visit http://www.tateandlyle.com.

SPLENDA® is a trademark of McNeil Nutritionals, LLC.

Copyright Business Wire 2015

Date   Source Headline
12th Mar 202111:00 amRNSDirector Declaration
1st Mar 202111:00 amRNSTotal Voting Rights
26th Feb 202111:00 amRNSDirector Declaration
15th Feb 20214:43 pmRNSHolding(s) in Company
15th Feb 20214:40 pmRNSHolding(s) in Company
15th Feb 20214:37 pmRNSHolding(s) in Company
10th Feb 202111:15 amRNSAcquisition
28th Jan 20217:00 amRNSTrading Statement
21st Jan 20217:00 amRNSVivid Sehgal Appointed Chief Financial Officer
12th Jan 20213:30 pmRNSDirector/PDMR Shareholding
4th Jan 20213:05 pmRNSBlock listing Interim Review
4th Jan 20213:04 pmRNSTotal Voting Rights
30th Dec 20201:00 pmRNSBoard Changes
7th Dec 202011:06 amRNSDirector/PDMR Shareholding
1st Dec 20207:00 amRNSTATE & LYLE ACQUIRES SWEET GREEN FIELDS
5th Nov 20207:00 amRNSHalf-year Report
28th Oct 20207:00 amRNSTate & Lyle to acquire tapioca business
14th Oct 202011:00 amRNSDirector Declaration
7th Oct 20207:00 amRNSDirectorate Change
2nd Oct 202011:55 amRNSDirector/PDMR Shareholding
1st Oct 20202:30 pmRNSTotal Voting Rights
17th Sep 20207:30 amRNSBlock Listing
8th Sep 202010:00 amRNSDirector/PDMR Shareholding
1st Sep 202012:00 pmRNSTotal Voting Rights
5th Aug 20204:30 pmRNSDirector/PDMR Shareholding
3rd Aug 20202:00 pmRNSTotal Voting Rights
23rd Jul 20201:00 pmRNSResult of AGM
23rd Jul 20207:00 amRNSTrading Statement
2nd Jul 20205:45 pmRNSBlock listing Interim Review
1st Jul 20203:06 pmRNSRights attaching to the listed share capital
1st Jul 20203:05 pmRNSTotal Voting Rights
9th Jun 20203:00 pmRNSAnnual Financial Report
2nd Jun 20203:56 pmRNSDirector/PDMR Shareholding
21st May 20207:00 amRNSFinal Results
4th May 20207:00 amRNSTrading Update
1st May 20203:27 pmRNSTotal Voting Rights
3rd Apr 202011:00 amRNSDirector Declaration
1st Apr 202012:26 pmRNSTotal Voting Rights
6th Feb 20207:00 amRNSTrading Statement
30th Jan 202011:45 amRNSDirector/PDMR Shareholding
7th Jan 20202:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202012:41 pmRNSBlock listing Interim Review
19th Dec 20192:00 pmRNSDirector/PDMR Shareholding
7th Nov 20197:00 amRNSHalf-year Report
3rd Oct 20193:06 pmRNSHolding(s) in Company
1st Oct 201910:14 amRNSTotal Voting Rights
19th Sep 20197:00 amRNSFULL PENSION SCHEME BUY-IN WITH LEGAL & GENERAL
6th Sep 201910:15 amRNSDirector/PDMR Shareholding
30th Aug 201912:00 pmRNSDirector Declaration
21st Aug 201910:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.